EVALUATING THE CLINICAL EFFICACY OF A POLYHERBAL FORMULATION AROGH PLUS ON STRESS – A RANDOMISED CLINICAL STUDY

Background : Stress is a common entity, widely spoken about among the working population, for which a safe and effective remedy is needed.Purpose of the study : To evaluate the clinical effectiveness of Arogh plus a polyherbal formulation, towards stress relieving properties in a randomized clinical trial in volunteers.Results : Ten volunteers from Marketing field, evaluated to be under stress, completed the full course. All were clinically evaluated based upon symptoms, anthropometric evaluation, hematological, diabetic and serum cortisol and urine profile. All the parameters were evaluated during 0 day, 15th day, 30th day and on 45th day after stopping the drug internally. Three grams of Arogh plus was given twice daily for a period of 30 days was found to decrease symptoms due to stress and the benefits was reinforced by way of significant reduction in serum cortisol with a reduction of 36.99 % within a month.Conclusion: Arogh plus is an effective formulation in relieving stress and improving the quality of life

Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study

Background Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a recently described autoinflammatory disorder with little therapeutic evidence. We compared treatment outcomes of targeted therapies versus prednisolone alone in the largest UK cohort of patients with VEXAS syndrome to date. Methods In this retrospective cohort study, we analysed the outcomes of targeted therapies in patients with VEXAS syndrome in six tertiary referral centres across the UK between July 22, 2014, and Oct 19, 2024. The inclusion criteria were genetically confirmed VEXAS syndrome and receipt of at least one targeted therapy or prednisolone alone. Patients without clinical information at all timepoints after baseline were excluded. Data collection forms were used to record clinical and biochemical data at the following timepoints: time of diagnosis, initiation of treatment, and follow-up at 3 months, 6 months, and 12 months from the initiation of treatment (±28 days). Laboratory parameters, including C-reactive protein (CRP) and haemoglobin, and glucocorticoid doses were collected at each timepoint and compared between timepoints. Primary outcomes were complete response (ie, clinical remission, CRP ≤10 mg/L, and prednisolone ≤10 mg per day) and partial response (ie, clinical remission with ≥50% reductions in both CRP and glucocorticoid dose from baseline) to treatment. Treatment discontinuation and adverse events were documented for each treatment. Due to the high prevalence of cytopenias in VEXAS syndrome, these were only recorded as adverse events when necessitating treatment change. People with lived experience were not involved in the study. Findings We analysed 71 targeted therapies in 59 patients with genetically confirmed VEXAS syndrome. Of the 59 patients, 58 (98%) were male and one (2%) was female, with a mean age of 71 years (SD 8), and 27 (46%) had myelodysplastic syndrome. The treatments included tocilizumab (n=19), anakinra (n=13), azacitidine (n=13), baricitinib (n=11), and prednisolone only (n=10). At 6 months, in those who continued therapy, ten (91%) of 11 patients receiving azacitidine showed a response (three [27%] complete responses), as well as did seven (64%) of 11 receiving tocilizumab (four [36%] complete responses), three (100%) of three receiving anakinra (one [33%] complete response), and two (40%) of five receiving baricitinib (no complete responses). Although all patients who tolerated anakinra had a response, the discontinuation rate was high (eight [62%] of 13), mostly due to severe injection-site reactions (n=5). Patients were more likely to respond to azacitidine than to other therapies at 6 months (risk ratio 2·47, 95% CI 1·18–5·20; p=0·018). Absence of fever or thromboembolism at diagnosis was associated with better outcomes. By 6 months, median CRP concentrations had decreased in patients receiving tocilizumab (from 30 mg/L [IQR 13–45] to 4 mg/L [3–37]) or anakinra (from 18 mg/L [11–52] to 2 mg/L [1–28]), whereas azacitidine showed the greatest increase in haemoglobin (from mean concentration 104 g/L [SD 17·5] to 120 g/L [14·4]). 28 (39%) of 71 treatments were discontinued, most commonly due to serious adverse events (12 [17%]) and death (nine [13%]). Infections were most frequent with azacitidine (eight [62%] of 13) and tocilizumab (nine [47%] of 19). Interpretation In this UK cohort of patients with VEXAS syndrome, azacitidine and tocilizumab showed superior effectiveness compared with anakinra, baricitinib, and prednisolone only. Treatment selection should consider individual risk factors and tolerability. Prospective studies are needed to confirm optimal treatment strategies and develop standardised protocols

City of Hitchcock Comprehensive Plan 2020-2040

Hitchcock is a small town located in Galveston County (Figure 1.1), nestled up on the Texas Gulf Coast. It lies about 40 miles south-east of Houston. The boundaries of the city encloses an area of land of 60.46 sq. miles, an area of water of 31.64 sq. miles at an elevation just 16 feet above sea level. Hitchcock has more undeveloped land (~90% of total area) than the county combined. Its strategic location gives it a driving force of opportunities in the Houston-Galveston Region.The guiding principles for this planning process were Hitchcock’s vision statement and its corresponding goals, which were crafted by the task force. The goals focus on factors of growth and development including public participation, development considerations, transportation, community facilities, economic development, parks, and housing and social vulnerabilityTexas Target Communitie

GASTRIC AND DUODENAL ANTIULCER AND CYTOPROTECTIVE EFFECTS OF CISSUS QUADRANGULARIS L. VARIAN II IN RATS.

Aqureous ethanolic extract of the aerial parts of Cissus quadrangularis L. variant II (Vitaceae) was found to possess antiulcer activities. It also has cytoprotective, mucin stimulation activities and selectively increased prostaglandin synthesis thereby decreasing the incidence of ulcer. Samples collected during the flowering period were effective than those at the vegetative period. Keywords: Cissus quadrangularis, Vitaceae, antiulcer activities, cytoprotective, mucin production, seasonal changes [Nig. J. Nat. Prod. And Med. Vol.6 2002: 10-14